Skip to main content
SpringerLink
Log in

Novel Statins: Pharmacological and Clinical Results

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Rosuvastatin (ZD4522) and pitavastatin (NK-104) are novel HMG-CoA reductase inhibitors with a peculiar pharmacological profile. In particular, they show a high potency in decreasing LDL-C and their catabolism is not mediated by the cytochrome P-450 3A4, thus reducing the potential for drug-drug interaction and improving the management of blood cholesterol. As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased LDL-C lowering potency may ensure the achievement of target LDL-C levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Blumenthal RS. Statins: Effective antiatherosclerotic therapy. Am Heart J 2000;139:577–583.

    Google Scholar 

  2. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207–213.

    Google Scholar 

  3. Adult Treatment Panel III. Executive summary of the third report of the national cholesterol education program (NCEP)expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 2001;285:2486–2493.

    Google Scholar 

  4. Brown BG, Zhao XQ, Sacco DE, Alberts JJ. Lipid lowering and plaque regression: New insight into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781–1791.

    Google Scholar 

  5. Smilde TJ, vanWissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hyperchoelsterolemia (ASAP): A prospective, randomized, double-blind trial. Lancet 2001;357:574–575.

    Google Scholar 

  6. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients withy coronary heart disease: The Scandinavian Survival Study (4S). Lancet 1994;344:1383–1389.

    Google Scholar 

  7. Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/ TexCAPS Study Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998;279:1615–1622.

    Google Scholar 

  8. The Long Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–1357.

    Google Scholar 

  9. Shepherd J, Cobbe SM, Ford I, et al. for theWest of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hyperchoelsterolemia. N Engl J Med 1995;333:1301–1307.

    Google Scholar 

  10. Sacks FM, Pfeffer MA, Moye LA, et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol. N Engl Med J 1996;335:1001–1009.

    Google Scholar 

  11. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001;285:1711–1718.

    Google Scholar 

  12. Bellosta S, Ferri N, Bernini F, Paoletti P, Corsini A. Nonlipid-related effects of statins. Ann Med 2000;32:164–176.

    Google Scholar 

  13. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413–428.

    Google Scholar 

  14. LaRosa JC. Pleiotropic effects of statins and their clinical significance. Am J Cardiol 2001;88:291–293.

    Google Scholar 

  15. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001;87:28B–32B.

    Google Scholar 

  16. Istvan ES, Deisenhofer J. Structural mechanisms for statin inhibition of HMG-CoA reductase. Science 2001;292:1160–1164.

    Google Scholar 

  17. Smith G, Davidson R, Bloor S, et al. Pharmacological properties of ZD 4522: A new HMG-CoA reductase inhibitor [Abstract]. Atherosclerosis 2000;151:39.

    Google Scholar 

  18. Buckett L, Ballard P, Davidson R, et al. Selectivity of ZD 4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells [Abstract]. Atherosclerosis 2000;151:41.

    Google Scholar 

  19. Brown CDA, Windass A, Bleasby K, Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OAPT-C [Abstract]. Atherosclerosis 2001;2:90.

    Google Scholar 

  20. Nezasa K, Higaki K, Hasegawa H, et al. Uptake of of HMGCoA reductase inhibitor ZD 4522 into hepatocytes and distribution into liver and other tissues of the rat [Abstract]. Atherosclerosis 2000;151:39.

    Google Scholar 

  21. Warwick MJ, Dane AL, Raza A, Schneck DV. Single-and multiple-dose pharmacokinetics and safety of the newHMGCoA reductase inhibitor ZD 4522 [Abstract]. Atherosclerosis 2000;151:39.

    Google Scholar 

  22. McCormick AD, McKillop D, Bulters CJ, et al. ZD 4522: An HMG-CoA reductase inhibitor free of metabolically medaited drug interactions: Metabolic studies in human in vitro systems [Abstract]. J Clin Pharmacol 2000;40:1055.

    Google Scholar 

  23. Corsini A. Fluvastatin: Effects beyond cholesterol lowering. J Cardiovasc Pharmacol Ther 2000;5:161–175.

    Google Scholar 

  24. Ballantyne C, Miller E, Chitra R. Rosuvastatin alone produces similar lipid benefits compared with rosuvastatin plus cholestyramine in patients with primary hypercholesterolemia [Abstract]. Presented at International Symposium on Drugs Affecting Lipid Metabolism (DALM), New York, NY, September 9–13, 2001.

  25. Olsson AG. A new statin: A new standard. Am J Manag Care 2001;7:S152–S154.

    Google Scholar 

  26. Caslake MJ, Stewart G, Day S, et al. Rosuvastatin normalises atherogenic levels of Apo B-containig lipoprotein subfractions [Abstract]. Presented at International Symposium on Drugs Affecting Lipid Metabolism (DALM), New York, NY, September 9–13, 2001.

  27. Davidson MH, Ma PTS, Stein E, et al. ZD 4522 is superior to atorvastatin in decreasing low-density lipoprotein cholesterol and increasing high-density lipoprotein cholesterol in patients with Type IIa or IIb hypercholesterolemia [Abstract]. J AmColl Cardiol 2001;37 (Suppl A):Abstract:1261–1275.

    Google Scholar 

  28. Olsson A, Southworth H, Wilpshaar JW. Long-term ef-ficacy and safety of rosuvastatin: Results of a 52-week comparator-controlled trial versus atorvastatin. Eur Heart J 2001;22(Suppl):253.

    Google Scholar 

  29. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolemic patients: A randomized, double-blind study. J Cardiovasc Risk 2001;8:383.

    Google Scholar 

  30. Brown WV, Chitra RR, Zedler BK, Bays HE, Hassman HA. Long-term efficacy and safety of rosuvastatin: Results of a 52-week comparator-controlled trial versus pravastatin and simvastatin. Eur Heart J 2001;22(Suppl):270.

    Google Scholar 

  31. Hunninghake DB, Chitra R, Simonson SG, Schneck DV. Effects of rosuvastatin on serum lipids and lipid subfraction in patients with hypertriglyceridemia (abstract). Presented at International Symposium on Drugs Affecting Lipid Metabolism (DALM), New York, NY, September 9–13, 2001.

  32. Shepherd J, Hunninghake D, Harris S, Hutchinson H, Pears J. A review of the safety profile of rosuvastatin in an international phase II/III clinical trila programme [Abstract]. Presented at International Symposium on Drugs Affecting Lipid Metabolism (DALM), New York, NY, September 9–13, 2001.

  33. Brown WV. Novel approaches to lipid lowering: What is on the horizon. Am J Cardiol 2001;87:23B–27B.

    Google Scholar 

  34. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: Impact of statin trials. Circulation 1998;97:946–952.

    Google Scholar 

  35. Knatterud GL, Rosenber Y, Campeau L, et al. Long-term effects on clinical outcomes of aggressive lowering of lowdensity lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Circulation 2000;103:157–165.

    Google Scholar 

  36. Stalker TJ, Lefer AM, Scalia R. Anew HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects in the microvascular endothelium: The role of mevalonic acid. Br J Pharmacol 2001;133:406–412.

    Google Scholar 

  37. Li W, Asagami T, McTaggart F, Tsao PS. Rosuvastatin inhibits monocyte/endothelial interactions in ApoE (-/-) mice [Abstract]. Presented at International Symposium on Drugs Affecting Lipid Metabolism(DALM),NewYork,NY, September 9–13, 2001.

  38. Copin C, Davidson R, McTaggart F, Chapman MJ, Fruchart JC, Rouis M. Rosuvastatin reduces MMP-9 and MMP-7 secretion by human monocytes-derived macrophages [Abstract]. Presented at International Symposium on Drugs Affecting Lipid Metabolism (DALM), New York, NY, September 9–13, 2001.

  39. Kaijnami K, Koizumi J, Ueda K, Miyamoto S, Takegoshi T, Mabuchi H, for the Hokuriku NK-104 Study Group. Effects of NK-104, a new hydroxmethylglutaryl-coenzyme reductase inhibitir, on low-density lipoprotein chelesterol in heterozygous familial hypercholesterolemia. Am J Cardiol 2000;85:178–183.

    Google Scholar 

  40. Fujino H, Kojina J, Yamada Y, Kanda H, Kimata H. Studies on the matabolic fate of NK-104, a new inhibitor of HMGCoA reductase (4): Interspecies variation in laboratory animals and humans. Xenobio Metabol Dispos 1999;14:79–81.

    Google Scholar 

  41. Fujino H, Yamada I, Shimada S, Matsumoto H, Yoneda M. Studies on the metabolic fate of itavastatin, a new inhibitor of HMG-CoA reductase-in vitro metabolism [Abstract]. Atherosclerosis 2000;151:50.

    Google Scholar 

  42. Ooyen C, Zecca A, Bersino AM, Catapano AL. NK-104, a potent 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells. Atherosclerosis 1999;145:85–87.

    Google Scholar 

  43. Aoki T, Yamazaki H, Suzuki H, et al. Cholesterol-lowering effect of NK-104, a 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung/Drug Res 2001;51:197–203.

    Google Scholar 

  44. Suzuki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Atherosclerosis 1999;146: 259–270.

    Google Scholar 

  45. Suzuki H, Yamazaki H, Aoki T, et al. Hypolipidemic effect of NK-104 and other 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors in guinea pigs. Arzneimittelforschung/Drug Res 2001;51:38–45.

    Google Scholar 

  46. Yamamoto K, Tokada N, Goto H, et al. Effect of NK-104, a new synthetic HMG-CoA reductase inhibitor, on triglyceride secretion and fatty acid oxidation in rat liver. Life Sci 1999;65:1493–1502.

    Google Scholar 

  47. Teramoto T, Saito Y, Nakaya N. Clinical evaluation of NK-104 (itavastatin) in long-term treatment of patients with hyperlipidemia [Abstract]. Atherosclerosis 2000;151:53.

    Google Scholar 

  48. Sasaki J, Ikeda Y, Yamamoto M, Ageta M, Arakawa K. Ef-ficacy and safety of a new HMG-CoA reductase inhibitor, NK-104, in patients with hypertrigliceridemia. Randomized double-blind, cross-over placebo controlled study [Abstract]. Atherosclerosis 2000;73.

  49. Mabuchi H, Hokuriku FH, Study Group. Long-term effi-cacy of NK-104 (itavastatin), a new HMG-CoA reductase inhibitor, in patients with heterozigous familial hyperchelesterolemia [Abstract]. Atherosclerosis 2000;151:53.

    Google Scholar 

  50. Takemoto M, Kitahara M, Yokotr K, et al. NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells. Br J Pharmacol 2001;133:83–88.

    Google Scholar 

  51. Majjan DP, Nicholson AC, Han J, Summers B, Feirt N, Gotto AM. NK-104 inhibits expression of VCAM-1 by endothelial cells and CD36, tissue factor and MMP-9 by macrophages. Presented at International Symposium on Drugs Affecting Lipid Metabolism (DALM), NewYork,NY, September 9–13,2001.

  52. Weitz-Schmidt G,Welzenbach C, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687–692.

    Google Scholar 

  53. Gotto A, Belch J, Pedersen TR, et al. The evaluation of atherosclerotic outcomes with rosuvastatin therapy (EARTH) study: A study in high-risk patients with below average LDL-cholesterol levels [Abstract]. Presented at International Symposium on Drugs Affecting Lipid Metabolism (DALM), New York, NY, September 9–13, 2001.

Download references

Author information

Authors and Affiliations

  1. Nutrition Foundation of Italy, Via S Pietro all'Orto, 17, 20121, Milan, Italy

    Chiara Bolego & Andrea Poli

  2. Department of Pharmacological Sciences, Via Balzaretti, 9, 20131, Milan, Italy

    Andrea Cignarella, Alberico L. Catapano & Rodolfo Paoletti

Authors
  1. Chiara Bolego
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Poli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Cignarella
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alberico L. Catapano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rodolfo Paoletti
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bolego, C., Poli, A., Cignarella, A. et al. Novel Statins: Pharmacological and Clinical Results. Cardiovasc Drugs Ther 16, 251–257 (2002). https://doi.org/10.1023/A:1020656607497

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1020656607497

Search

Navigation